“…Furthermore, the available data suggest seronegative patients have a different clinical evolution and should therefore be evaluated separately. Another factor that is common in HIV patients and that is known to affect [46] Iran 3 (13.6) 2 (9.1) ND 1 (4.5) Bagaglio et al [47] Italy 9 (31.0) 9 (31.0) ND ND Bell et al [48] Africa [51] Spain 6 (2.4) 2 (0.8) 4 (1.6) ND Filippini et al [13] Italy 17 (20.0) 11 (12.8) 3 (3.5) 3 (3.5) Firnhaber et al [23] Africa 38 (88.4) 38 (88.4) ND ND Gupta et al [30] India 24 (45.3) 13 (24.5) 11 (20.8) ND Hakeem et al [52] Scotland 2 (2.8) 2( 2.9) ND ND Jardim et al [19] Brazil 8 (5.0) 2 (1.3) 6 (3.8) ND Khamduang et al [35] Thailand 47 (23.5) 47 (23.5) ND ND Liang et al [53] Taiwan 3 (2.3) 3 (2.3) ND ND Lo Re et al [54] United States 17 (10.0) 10 (5.6) 7 (3.9) ND Loustaud-Ratti et al [55] France [24] Africa 51 (10.0) 51 (11.8) ND ND Neau et al [58] France 1 (0.6) 1 (0.6) ND ND Nebbia et al [59] England 48 (14.0) 48 (14.0) ND ND Opaleye et al [25] Nigeria 21 (11.2) 8 (4.3) 9 (4.8) 2 (1.1) Panigrahi et al [26] India 12 (10.7) 9 (8.0) 3 (2.7) ND Santos et al [20] Brazil 16 (15.8) 2 4 (4.0) 12 (11.9) ND Sen et al [27] India 1 (5.6) 2 1 (5.6) ND ND Shire et al [60] United States 4 (10.5) 4 (10.5) ND ND Shire et al [61] United States 12 (30.2) 3 (7.0) 5 1 (11.6) 5 (11.6) Sucupira et al [21] Brazil 6 (18.8) 2 3 (9.4) 3 (9.4) ND Torres Barranda et al [22] Mexico 7 (18.4) 1 (2.6) 1 (2.6) 5 (13.2) Tramuto et al [62] Italy 24 (5.9) 8 (2.0) 7 1 (1.7) 9 (2.2) Tsui et al [63] United States 8 (2.0) 8 (2.0) ND ND 1 In some studies the anti-HBsAg positive group was also included; 2 Prevalence calculated using the reported data; anti-HBsAg+, antibodies against hepatitis B surface antigen positive; anti-HBcAg+ antibodies against hepatitis B core antigen positive. Prevalence (%) were included for each group of patients studied according the HBV serological markers (Anti-HBsAg-/anti-HBcAg+, Anti-HBsAg+/anti-HBcAg+, Anti-HBsAg-/anti-HBcAg-).…”
“…Furthermore, the available data suggest seronegative patients have a different clinical evolution and should therefore be evaluated separately. Another factor that is common in HIV patients and that is known to affect [46] Iran 3 (13.6) 2 (9.1) ND 1 (4.5) Bagaglio et al [47] Italy 9 (31.0) 9 (31.0) ND ND Bell et al [48] Africa [51] Spain 6 (2.4) 2 (0.8) 4 (1.6) ND Filippini et al [13] Italy 17 (20.0) 11 (12.8) 3 (3.5) 3 (3.5) Firnhaber et al [23] Africa 38 (88.4) 38 (88.4) ND ND Gupta et al [30] India 24 (45.3) 13 (24.5) 11 (20.8) ND Hakeem et al [52] Scotland 2 (2.8) 2( 2.9) ND ND Jardim et al [19] Brazil 8 (5.0) 2 (1.3) 6 (3.8) ND Khamduang et al [35] Thailand 47 (23.5) 47 (23.5) ND ND Liang et al [53] Taiwan 3 (2.3) 3 (2.3) ND ND Lo Re et al [54] United States 17 (10.0) 10 (5.6) 7 (3.9) ND Loustaud-Ratti et al [55] France [24] Africa 51 (10.0) 51 (11.8) ND ND Neau et al [58] France 1 (0.6) 1 (0.6) ND ND Nebbia et al [59] England 48 (14.0) 48 (14.0) ND ND Opaleye et al [25] Nigeria 21 (11.2) 8 (4.3) 9 (4.8) 2 (1.1) Panigrahi et al [26] India 12 (10.7) 9 (8.0) 3 (2.7) ND Santos et al [20] Brazil 16 (15.8) 2 4 (4.0) 12 (11.9) ND Sen et al [27] India 1 (5.6) 2 1 (5.6) ND ND Shire et al [60] United States 4 (10.5) 4 (10.5) ND ND Shire et al [61] United States 12 (30.2) 3 (7.0) 5 1 (11.6) 5 (11.6) Sucupira et al [21] Brazil 6 (18.8) 2 3 (9.4) 3 (9.4) ND Torres Barranda et al [22] Mexico 7 (18.4) 1 (2.6) 1 (2.6) 5 (13.2) Tramuto et al [62] Italy 24 (5.9) 8 (2.0) 7 1 (1.7) 9 (2.2) Tsui et al [63] United States 8 (2.0) 8 (2.0) ND ND 1 In some studies the anti-HBsAg positive group was also included; 2 Prevalence calculated using the reported data; anti-HBsAg+, antibodies against hepatitis B surface antigen positive; anti-HBcAg+ antibodies against hepatitis B core antigen positive. Prevalence (%) were included for each group of patients studied according the HBV serological markers (Anti-HBsAg-/anti-HBcAg+, Anti-HBsAg+/anti-HBcAg+, Anti-HBsAg-/anti-HBcAg-).…”
“…An interesting observation was recently reported in the study by Dapena et al (38) in which of 17 children co-infected, 2 (12%) were HCV RNA positive but anti-HCV negative, suggesting that antibodies assays for HCV in the context of co-infection could miss some cases of seronegative hepatitis C.…”
Section: Viremia and Alanine Aminotransferase Levels In Co-infected Cmentioning
confidence: 82%
“…In the Spanish prospective study, the rate of spontaneous clearance was 17.5% in monoinfected children while no co-infected child spontaneously cleared the virus (32). Overall, only 12 children across the different HCV/HIV reported pediatric cohorts presented spontaneous clearance of HCV and no data were provided on its timing (3,27,(32)(33)(34)38).…”
Section: Spontaneous Clearance Of Hcv In Co-infected Childrenmentioning
The effect of HIV co-infection on HCV-related disease was clear with most studies indicating that HIV accelerates HCV progression and reduces the efficacy of the available anti-HCV therapies.
“…Studies in adults with chronic liver disease (CLD) have shown a variable prevalence of OBI ranging from 2 to 32% depending on the prevalence of HBV infection in the particular general population and the sensitivity of the assay used for detection of HBV DNA [4,5]. However, studies on OBI in children are limited largely to those with hematological disorders and HIV infection [6,7].The current study aimed to prospectively evaluate the prevalence of OBI in children with CLD.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.